LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
30 Abril 2024 - 8:00AM
Business Wire
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology
company, today announced Ahmet Tezel, Ph.D., will join the Company
as Chief Innovation Officer (CINO), effective May 13, 2024. In this
newly created position, Tezel will leverage his career of more than
20 years in research and development (R&D) to establish an
integrated innovation function at LivaNova that will accelerate the
Company’s development of new technologies. In this capacity, Tezel
will join the LivaNova Executive Leadership Team.
“I am very pleased to welcome Ahmet to the LivaNova team. At
LivaNova, our commitment to pioneering innovation remains
unwavering, and Ahmet's arrival marks a significant step in
advancing this vision. With a remarkable track record, Ahmet has
led teams that have developed market-leading technologies across
diverse medical domains, from bariatric surgery to surgical
ophthalmology. As Chief Innovation Officer, Ahmet will advance
LivaNova’s ability to create novel solutions and elevate the
quality of care in neurological and cardiac health for patients
around the world,” said Vladimir Makatsaria, Chief Executive
Officer of LivaNova.
Tezel most recently served as Company Group Chairman at Johnson
& Johnson MedTech, leading its Global R&D and Innovation
teams. Throughout his career, he has held executive R&D roles
at several healthcare companies, including Ethicon, Alcon Inc. and
Allergan Inc., developing Class III implantables and complex
capital equipment.
“I look forward to this new chapter at LivaNova, working with
the team to harness their motivations and talents to drive
innovative product development that creates long-term value for the
Company and aligns with its mission,” said Tezel. “I am honored to
join a company that has a profound impact on patients.”
Tezel earned a Bachelor of Science and a Master of Science in
chemical engineering from Bogazici University in Türkiye and a
doctorate in chemical engineering from the University of
California-Santa Barbara, where he focused on transdermal drug
delivery.
About LivaNova
LivaNova PLC is a global medical technology company built on
nearly five decades of experience and a relentless commitment to
provide hope for patients and their families through medical
technologies, delivering life-changing improvements for both the
Head and Heart. Headquartered in London, LivaNova employs
approximately 2,900 employees and has a presence in more than 100
countries for the benefit of patients, healthcare professionals and
healthcare systems worldwide. For more information, please visit
www.livanova.com.
Safe Harbor Statement
This news release contains “forward-looking statements”
concerning the Company’s goals, beliefs, expectations, strategies,
objectives, plans, underlying assumptions and other statements that
are not necessarily based on historical facts. These statements
include, but are not limited to, statements regarding the executive
leadership of the Company. Actual events may differ materially from
those indicated in our forward-looking statements as a result of
various factors, including those factors set forth in Item 1A of
the Company’s most recent Annual Report on Form 10-K, as
supplemented by any risk factors contained in Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no
obligation to update the information contained in this press
release to reflect subsequently occurring events or
circumstances.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430832738/en/
LivaNova Investor Relations and Media Contacts +1 281-895-2382
Briana Gotlin Director, Investor Relations
InvestorRelations@livanova.com Deanna Wilke VP, Corporate
Communications Corporate.Communications@livanova.com
LivaNova (NASDAQ:LIVN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
LivaNova (NASDAQ:LIVN)
Gráfica de Acción Histórica
De May 2023 a May 2024